Tapestry Names Rowinsky, Cannon to Board

Tapestry Pharmaceuticals Inc., a developer of cancer-related medicines, reported this week that it has appointed Eric K. Rowinsky, M.D., and Martin Cannon to its board of directors. Rowinsky is senior vice president and chief medical officer for ImClone Systems Inc., while Cannon is president and chief executive officer for New Health Sciences Inc. Both will serve on Tapestry's board as independents. In a related announcement, Tapestry said Arthur Hayes Jr., M.D., has resigned from its board after 11 years of service. The Boulder, Colo.-based company said Hayes cited a potential conflict of fiduciary interests as reason for stepping down. Tapestry Pharmaceuticals currently has a candidate drug, TPI 287, in multiple Phase 2 clinical studies.